Table 2.

Immunotherapy regimens adopted in the present study

Study name	Regimens	References
KEYNOTE 010/024/042	○ Pembrolizumab	1–3
IMpower110/OAK	○ Atezolizumab	4 5
CheckMate 017/057	○ Nivolumab	6
KEYNOTE 189	○ Pembrolizumab + carboplatin/cisplatin + pemetrexed	7
KEYNOTE 407	○ Pembrolizumab + carboplatin + nab-paclitaxel	8
IMpower130	○ Atezolizumab + carboplatin + nab-paclitaxel	9
IMpower132	○ Atezolizumab + carboplatin/cisplatin + pemetrexed	10
IMpower150	○ Atezolizumab+ bevacizumab + carboplatin+ paclitaxel	11
CheckMate 227	○ Nivolumab+ ipilimumab	12
CheckMate 9LA	○ Nivolumab+ ipilimumab + carboplatin/cisplatin + pemetrexed	13
CheckMate 9LA	○ Nivolumab+ ipilimumab + carboplatin+ nab-paclitaxel	13
IMpower133	○ Atezolizumab + carboplatin + etoposide	14
CASPIAN	○ Durvalumab + carboplatin/cisplatin + etoposide	15